TapewireFind a company

person · Reporting owner

Gayer Charles K

Disclosed activity across 1 company

Tapewire entity
70918
SEC CIK
0001800110

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315President and CCODecember 19, 2025December 23, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOCRYST PHARMACEUTICALS INC

Report date December 19, 2025 · Filed December 23, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect952,583 Ending reported balance After 2025-12-22 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2025-12-19 · Tax withholding · Disposed 11,477 · Balance 878,350

F1: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

Row 2 · 2025-12-22 · Exercise / conversion · Acquired 14,142 · Balance 892,492

Row 3 · 2025-12-22 · Exercise / conversion · Acquired 10,091 · Balance 902,583

Row 4 · 2025-12-22 · Exercise / conversion · Acquired 50,000 · Balance 952,583

Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2026-05-23Direct0 Reported balance After 2025-12-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-12-22 · Exercise / conversion · Disposed 14,142 · Balance 0

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2027-12-20Direct17,409 Reported balance After 2025-12-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-12-22 · Exercise / conversion · Disposed 10,091 · Balance 17,409

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2027-02-27Direct0 Reported balance After 2025-12-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-12-22 · Exercise / conversion · Disposed 50,000 · Balance 0

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

F2: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $5.51 $0.00
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · derivative · entry 7

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 10,091 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · derivative · entry 6

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,409

Underlying: Common Stock · 10,091 shares

Expires 2027-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 14,142 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · derivative · entry 5

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,142 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 50,000 $5.51 $275,500.00
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · nonDerivative · entry 4

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 952,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 10,091 $5.04 $50,858.64
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · nonDerivative · entry 3

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 902,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Exercise / conversionCommon Stock 14,142 $3.22 $45,537.24
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · nonDerivative · entry 2

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 892,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 19, 2025 Filed Dec 23, 2025 21:08 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 11,477 $7.41 $85,044.57
Disclosure

SEC source: 0000882796-25-000041 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 878,350

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:20 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 986,950 $0.00 Strike: $7.13 $0.00
Disclosure

SEC source: 0001171843-25-008038 · ownership.xml · derivative · entry 2

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 986,950

Underlying: Common Stock · 986,950 shares

Expires 2035-12-17

F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:20 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 471,000 $0.00 $0.00
Disclosure

SEC source: 0001171843-25-008038 · ownership.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 889,827

F1 · shares: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 12, 2025 Filed Dec 16, 2025 21:21 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 8,181 $7.57 $61,930.17
Disclosure

SEC source: 0000882796-25-000036 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · President and CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 418,827

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:19 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 260,950 $0.00 Strike: $7.39 $0.00
Disclosure

SEC source: 0001127602-24-029971 · form4.xml · derivative · entry 3

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,950

Underlying: Common Stock · 260,950 shares

Expires 2034-12-19

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:19 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 2,461 $7.39 $18,186.79
Disclosure

SEC source: 0001127602-24-029971 · form4.xml · nonDerivative · entry 2

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423,546

F2 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

Read SEC document
December 19, 2024 Filed Dec 23, 2024 21:19 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 125,950 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-029971 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 426,007

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2024 Filed Dec 17, 2024 21:22 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 8,251 $7.53 $62,130.03
Disclosure

SEC source: 0001127602-24-029602 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,057

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

Read SEC document
May 13, 2024 Filed May 15, 2024 11:04 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 PurchaseCommon Stock 30,000 $5.47 $164,100.00
Disclosure

SEC source: 0001127602-24-015363 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,533

Read SEC document
December 19, 2023 Filed Dec 20, 2023 21:38 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 2,482 $6.05 $15,016.10
Disclosure

SEC source: 0001127602-23-030185 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,533

F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 158,500 $0.00 Strike: $6.43 $0.00
Disclosure

SEC source: 0001127602-23-029833 · form4.xml · derivative · entry 3

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,500

Underlying: Common Stock · 158,500 shares

Expires 2033-12-14

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 Tax withholdingCommon Stock 5,840 $6.43 $37,551.20
Disclosure

SEC source: 0001127602-23-029833 · form4.xml · nonDerivative · entry 2

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,015

F2 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:40 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 34,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-029833 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,855

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:34 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 158,500 $0.00 Strike: $10.63 $0.00
Disclosure

SEC source: 0001127602-22-028076 · form4.xml · derivative · entry 2

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,500

Underlying: Common Stock · 158,500 shares

Expires 2032-12-19

F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:34 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 34,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-028076 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,610

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:48 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 SaleCommon Stock 6,100 $10.90 $66,490.00
Disclosure

SEC source: 0001127602-22-027875 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,610

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 20,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 22:12 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 164,000 $0.00 Strike: $11.43 $0.00
Disclosure

SEC source: 0001127602-21-031137 · form4.xml · derivative · entry 2

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,000

Underlying: Common Stock · 164,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 22:12 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 125,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-031137 · form4.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,556

F1 · shares: Annual award of Restricted Stock Units which will vest at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
December 14, 2021 Filed Jan 13, 2022 21:38 UTC Amendment BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-001454 · form4a.xml · nonDerivative · entry 1

Gayer Charles K · CIK 0001800110 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,556

F1 · shares: The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 21:37 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantEmp. Stock Option (Right to Buy) · Derivative 190,000 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001127602-20-031795 · form4.xml · derivative · entry 1

Gayer Charles K · CIK 0001800110 · Vice President and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.